Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pathologic Complete Response”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07301138
What this trial is testing

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Who this might be right for
Acute Lymphoblastic Leukemia
Ruijin Hospital 23
Not applicableStudy completedNCT06631066
What this trial is testing

Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients

Who this might be right for
Breast Cancer Female
National Cancer Institute, Egypt 160
Not applicableEnded earlyNCT01984866
What this trial is testing

CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.

Who this might be right for
Triple Negative, HER2+, Luminal B Breast Tumors (Stages II-III)in Female Patients
Hospital General Universitario Gregorio Marañon 13
Large-scale testing (Phase 3)Ended earlyNCT00362466
What this trial is testing

Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Who this might be right for
Leukemia
Bristol-Myers Squibb 3
Not applicableUnknownNCT03351959
What this trial is testing

Complete Pathologic Response Rectal Cancers

Who this might be right for
Rectal Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,000
Testing effectiveness (Phase 2)Study completedNCT01342679
What this trial is testing

Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

Who this might be right for
Chronic Myeloid Leukemia
Kanto CML Study Group 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07780877
What this trial is testing

Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer

Who this might be right for
Head & Neck Squamous Cell CarcinomaLocally Advanced Head and Neck Squamous Cell Carcinoma
Fudan University 85
Testing effectiveness (Phase 2)UnknownNCT01887561
What this trial is testing

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Who this might be right for
Myelogenous Leukemia, Chronic, Chronic Phase
Kanto CML Study Group 100
Not applicableActive Not RecruitingNCT06243679
What this trial is testing

The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

Who this might be right for
Resectable/Potentially Resectable NSCLC
Xiangya Hospital of Central South University 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT07021261
What this trial is testing

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Who this might be right for
Breast CancerTNBC
Fudan University 440
Very early researchActive Not RecruitingNCT03832569
What this trial is testing

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Who this might be right for
Solid TumorsIdentified by NGS, PCR or IHC
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07466303
What this trial is testing

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Who this might be right for
Breast CancerSerplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Xijing Hospital 84
Not applicableStudy completedNCT07473466
What this trial is testing

Evaluation of Reminder Strategies (Emails and Text Messages) to Increase Participation in the Le French Gut E-cohort

Who this might be right for
General Population (no Specific Condition or Disease)
SKEZI 20,487
Not applicableLooking for participantsNCT04643041
What this trial is testing

Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

Who this might be right for
Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University 47
Testing effectiveness (Phase 2)WithdrawnNCT01843179
What this trial is testing

Sulindac for Patients With AML

Who this might be right for
Acute Myeloid Leukemia
Massachusetts General Hospital
Testing effectiveness (Phase 2)UnknownNCT04848454
What this trial is testing

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Who this might be right for
HER2-negative Breast CancerNeoadjuvant TherapyPathological Complete Response+3 more
Peking University First Hospital 30
Testing effectiveness (Phase 2)UnknownNCT02670109
What this trial is testing

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

Who this might be right for
Triple-Negative Invasive Breast CarcinomaResidual Tumor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04335669
What this trial is testing

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Who this might be right for
Breast CancerTriple Negative Breast Neoplasms
Lund University Hospital 325
Testing effectiveness (Phase 2)Study completedNCT00545688
What this trial is testing

Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 417
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07618793
What this trial is testing

Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma

Who this might be right for
Lung Squamous Cell CarcinomaCarcinoma, Non-Small-Cell Lung (NSCLC)
zhang yi 60
Next Page